知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

92 条记录 (耗时 0.028 秒)

    GENES ENCODING NEMATODE TOXINS
    5.
    发明申请
    GENES ENCODING NEMATODE TOXINS 有权
    基因编码NEMATODE毒素

    公开(公告)号：US20130133107A1

    公开(公告)日：2013-05-23

    申请号：US13747740

    申请日：2013-01-23

    申请人： Athenix Corporation

    发明人： Cheryl L. Peters ,  Brian Vande Berg ,  Brian Carr ,  Julia T. Daum ,  Vadim Beilinson ,  Sandra Volrath ,  Candace Poutre ,  Kimberly Sampson

    IPC分类号： C12N15/82

    CPC分类号： C12N15/8241 ,  C12N9/0059 ,  C12N9/0071 ,  C12N15/8285 ,  C12Y110/03001 ,  C12Y114/18001 ,  Y02A40/164

    摘要： Compositions and methods for conferring nematicidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions including a coding sequence for nematicidal polypeptides are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also include transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated nematicidal nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed. In particular, the present invention provides for isolated nucleic acid molecules including nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:4, 5, 8, 9, 13, 14, 47, 48, or 49, the nucleotide sequence set forth in SEQ ID NO:1, 2, 3, 6, 7, 10, 11, 12, 15, 45, or 46, as well as variants and fragments thereof.

    摘要翻译： 提供了赋予细菌，植物，植物细胞，组织和种子的杀线虫活性的组合物和方法。 提供了包含杀线虫多肽的编码序列的组合物。 编码序列可用于DNA构建体或表达盒中，用于在植物和细菌中转化和表达。 组合物还包括转化的细菌，植物，植物细胞，组织和种子。 特别地，提供了分离的杀线虫剂核酸分子。 另外，包括对应于多核苷酸的氨基酸序列。 特别地，本发明提供了分离的核酸分子，其包括编码SEQ ID NO：4,5,8,9,13,14,77,48或49所示氨基酸序列的核苷酸序列，所列出的核苷酸序列 在SEQ ID NO：1,2,3,6,7,10,11，12，15，45或46中，以及其变体和片段。

    Nucleic acid molecule comprising a nucleic acid sequence which codes for a haemocyanin, and comprising at least one intron sequence
    7.
    发明授权
    Nucleic acid molecule comprising a nucleic acid sequence which codes for a haemocyanin, and comprising at least one intron sequence 有权
    核酸分子，其包含编码血蓝蛋白的核酸序列，并且包含至少一个内含子序列

    公开(公告)号：US07125557B1

    公开(公告)日：2006-10-24

    申请号：US10049988

    申请日：2000-08-21

    申请人： Jürgen Markl ,  Benjamin Altenhein ,  Bernhard Lieb ,  Thomas Stiefel

    发明人： Jürgen Markl ,  Benjamin Altenhein ,  Bernhard Lieb ,  Thomas Stiefel

    IPC分类号： A61K47/00 ,  C07K14/00

    CPC分类号： C12Y110/03001 ,  A61K38/00 ,  A61K48/00 ,  A61K2039/53 ,  C07K14/43504 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/21 ,  C12N9/0059 ,  G01N33/57496 ,  Y02A50/423 ,  Y10S530/855

    摘要： A nucleic acid molecule or construct alone or with a promoter suitable for expression control is contemplated that codes for a haemocyanin, a haemocyanin domain or a fragment thereof with the immunological properties of at least one domain of haemocyanin, and comprises at least one intron sequence, as well as haemocyanin fusion proteins. The construct furthermore can comprise a nucleic acid sequence that codes for an antigen. Host cells are also contemplated that contain the nucleic acid molecule or construct and a recombinant expression product thereof. The invention furthermore relates to a pharmaceutical composition that comprises the expression product and antibodies obtainable by immunization of an animal therewith, as well as the use the antibodies in screening methods for the identification of tumors.

    摘要翻译： 预期单独或具有适用于表达控制的启动子的核酸分子或构建体编码具有至少一个血蓝蛋白结构域的免疫学特性的血蓝蛋白，血蓝蛋白结构域或其片段，并且包含至少一个内含子序列， 以及血蓝蛋白融合蛋白。 该构建体还可以包含编码抗原的核酸序列。 还考虑了含有核酸分子或构建体及其重组表达产物的宿主细胞。 本发明还涉及一种药物组合物，其包含表达产物和通过用其免疫动物可获得的抗体，以及在用于鉴定肿瘤的筛选方法中使用该抗体。

    Compositions and methods relating to reduction of symptoms of autism
    8.
    发明授权
    Compositions and methods relating to reduction of symptoms of autism 失效
    与减少自闭症症状有关的组成和方法

    公开(公告)号：US06821514B2

    公开(公告)日：2004-11-23

    申请号：US10313790

    申请日：2002-12-06

    申请人： Devin B. Houston

    发明人： Devin B. Houston

    IPC分类号： A61K3848

    CPC分类号： C12N9/48 ,  A61K38/4813 ,  C12N9/0059 ,  C12Y110/03001 ,  C12Y304/14005 ,  A61K2300/00

    摘要： Methods and compositions that can reduce the symptoms of autism in a human patient comprising administering a physiologically effective amount of one or both of a purified casomorphin inhibitor selected from the group consisting of a casomorphinase and a casomorphin ligand, and a physiologically effective amount of a purified gluteomorphin inhibitor selected from the group consisting of a gluteomorphinase and a gluteomorphin ligand, to a human patient in sufficient quantities to reduce the effects of the autism. In some embodiments, the compositions and methods further comprise a physiologically effective amount of an enkephalin inhibitor, preferably an enkephalinase, and a physiologically effective amount of an endorphin inhibitor, preferably an endorphinase.

    摘要翻译： 可以减轻人类患者自闭症症状的方法和组合物，其包括给予生理学有效量的选自下列药物的一种或两种纯化的casomorphin抑制剂：胱天肽酶和casomorphin配体，以及生理有效量的纯化 麝香草素抑制剂，选自糠醛吗啡酶和钆蓝霉素配体，以足够的量向人类患者减轻自闭症的作用。 在一些实施方案中，组合物和方法还包含生理有效量的脑啡肽抑制剂，优选脑啡肽酶和生理有效量的内啡肽抑制剂，优选内啡肽。

    Compositions and methods relating to reduction of symptoms of autism
    9.
    发明申请
    Compositions and methods relating to reduction of symptoms of autism 失效

    公开(公告)号：US20030170227A1

    公开(公告)日：2003-09-11

    申请号：US10313790

    申请日：2002-12-06

    发明人： Devin B. Houston

    IPC分类号： A61K038/48

    CPC分类号： C12N9/48 ,  A61K38/4813 ,  C12N9/0059 ,  C12Y110/03001 ,  C12Y304/14005 ,  A61K2300/00

    摘要： Methods and compositions that can reduce the symptoms of autism in a human patient comprising administering a physiologically effective amount of one or both of a purified casomorphin inhibitor selected from the group consisting of a casomorphinase and a casomorphin ligand, and a physiologically effective amount of a purified gluteomorphin inhibitor selected from the group consisting of a gluteomorphinase and a gluteomorphin ligand, to a human patient in sufficient quantities to reduce the effects of the autism. In some embodiments, the compositions and methods further comprise a physiologically effective amount of an enkephalin inhibitor, preferably an enkephalinase, and a physiologically effective amount of an endorphin inhibitor, preferably an endorphinase.